Ying-Jun Chang

List of Publications by Year
in descending order

235 papers	4,750 citations	117625 34 h-index	161849 54 g-index
246 all docs	246 docs citations	246 times ranked	3970 citing authors

#	Article	IF	Citations
1	Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 2014, 124, 843-850.	1.4	285
2	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology and Oncology, 2015, 8, 84.	17.0	160
3	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Journal of Hematology and Oncology, 2017, 10, 134.	17.0	132
4	Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1465-1473.	2.0	114
5	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood, 2012, 119, 5584-5590.	1.4	107
6	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. Journal of Clinical Oncology, 2016, 34, 1855-1863.	1.6	100
7	Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?. Blood Reviews, 2013, 27, 55-62.	5.7	89
8	Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 440-449.	2.0	88
9	Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus. Journal of Infectious Diseases, 2017, 216, 945-956.	4.0	82
10	Immune Reconstitution Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation Compared with HLA-Identical Sibling Transplantation. Journal of Clinical Immunology, 2012, 32, 268-280.	3.8	81
11	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. Journal of Hematology and Oncology, 2016, 9, 35.	17.0	78
12	The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Annals of Hematology, 2015, 94, 1699-1705.	1.8	77
13	Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2008, 14, 323-334.	2.0	72
14	Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. Journal of Clinical Oncology, 2020, 38, 3367-3376.	1.6	69
15	Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to <scp>G</scp>-<scp>CSF</scp>-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2015, 90, E9-E16.	4.1	66
16	Platelet Engraftment in Patients with Hematologic Malignancies following Unmanipulated Haploidentical Blood and Marrow Transplantation: Effects of CD34+ Cell Dose and Disease Status. Biology of Blood and Marrow Transplantation, 2009, 15, 632-638.	2.0	63
17	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. Cancer, 2017, 123, 2881-2892.	4.1	63
18	Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1582-1587.	7.1	59

#	Article	IF	Citations
19	Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 197-204.	2.0	58
20	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cellular and Molecular Immunology, 2021, 18, 1172-1185.	10.5	55
21	Aging-induced IL27Ra signaling impairs hematopoietic stem cells. Blood, 2020, 136, 183-198.	1.4	53
22	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 44.	17.0	51
23	MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. Blood, 2018, 131, 1974-1986.	1.4	51
24	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. American Journal of Hematology, 2019, 94, 512-521.	4.1	51
25	Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Frontiers in Immunology, 2018, 9, 3041.	4.8	50
26	Association between an Impaired Bone Marrow Vascular Microenvironment and Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1190-1197.	2.0	49
27	Ceramide synthesis regulates T cell activity and GVHD development. JCI Insight, 2017, 2, .	5.0	49
28	Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Seminars in Hematology, 2016, 53, 82-89.	3.4	48
29	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. Journal of Hematology and Oncology, 2020, 13, 27.	17.0	48
30	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Advances, 2019, 3, 1303-1317.	5.2	43
31	Recipient expression of ligands for donor inhibitory KIRs enhances NKâ€cell function to control leukemic relapse after haploidentical transplantation. European Journal of Immunology, 2015, 45, 2396-2408.	2.9	42
32	Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Current Opinion in Hematology, 2012, 19, 454-461.	2.5	40
33	Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Annals of Hematology, 2012, 91, 427-437.	1.8	40
34	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood, 2018, 131, 1219-1233.	1.4	40
35	Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. Biology of Blood and Marrow Transplantation, 2018, 24, 1350-1359.	2.0	39
36	ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica, 2015, 100, 585-594.	3.5	38

#	Article	IF	Citations
37	Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review. Clinical Transplantation, 2011, 25, 13-23.	1.6	36
38	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells and Development, 2017, 26, 1648-1661.	2.1	36
39	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Frontiers in Immunology, 2019, 10, 2516.	4.8	36
40	Haploidentical Bone Marrow Transplantation Without T-Cell Depletion. Seminars in Oncology, 2012, 39, 653-663.	2.2	35
41	Early myeloid-derived suppressor cells (HLA-DRâˆ'/lowCD33+CD16âˆ') expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. Journal of Hematology and Oncology, 2019, 12, 31.	17.0	35
42	Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1376-1382.	2.0	33
43	Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transplantation, 2020, 55, 1326-1336.	2.4	31
44	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)â€"specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 70, 1429-1437.	5.8	30
45	Conflicting Impact of Alloreactive NK Cells on Transplantation Outcomes after Haploidentical Transplantation: Do the Reconstitution Kinetics of Natural Killer Cells Create These Differences?. Biology of Blood and Marrow Transplantation, 2011, 17, 1436-1442.	2.0	29
46	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemiaâ€"Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 929-936.	2.0	28
47	Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. OncoImmunology, 2017, 6, e1284721.	4.6	28
48	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. OncoImmunology, 2017, 6, e1356152.	4.6	28
49	Update of the â€œBeijing Protocolâ€•haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 703-707.	2.4	28
50	miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. Molecular Therapy - Nucleic Acids, 2020, 20, 764-776.	5.1	28
51	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1637-1643.	1.8	27
52	The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leukemia and Lymphoma, 2017, 58, 1135-1143.	1.3	27
53	Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Annals of Hematology, 2018, 97, 967-975.	1.8	27
54	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Science Bulletin, 2018, 63, 1376-1382.	9.0	27

#	Article	IF	Citations
55	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2019, 3, 4312-4325.	5.2	27
56	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clinical Cancer Research, 2019, 25, 1737-1748.	7.0	26
57	Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 45-56.	3.4	26
58	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1936-1943.	2.0	25
59	All-*trans* retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement–interleukin-1β loop. Haematologica, 2019, 104, 1661-1675.	3.5	25
60	Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transplant Immunology, 2009, 21, 228-233.	1.2	24
61	Haploidentical stem cell transplantation for the treatment of leukemia: current status. Expert Review of Hematology, 2014, 7, 635-647.	2.2	24
62	Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts. Journal of Translational Medicine, 2015, 13, 145.	4.4	24
63	Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. Journal of Translational Medicine, 2015, 13, 391.	4.4	24
64	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clinical Immunology, 2018, 190, 32-40.	3.2	24
65	Influence of Lymphocyte Recovery on Outcome of Haploidentical Transplantation for Hematologic Malignancies. Medicine (United States), 2009, 88, 322-330.	1.0	23
66	Inverse correlation of Vδ2^{+} T‐cell recovery with EBV reactivation after haematopoietic stem cell transplantation. British Journal of Haematology, 2018, 180, 276-285.	2.5	23
67	Newly Generated CD4+ T Cells Acquire Metabolic Quiescence after Thymic Egress. Journal of Immunology, 2018, 200, 1064-1077.	0.8	23
68	Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation. Journal of Immunology Research, 2014, 2014, 1-12.	2.2	22
69	Viral encephalitis after haplo‐identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. European Journal of Haematology, 2017, 98, 450-458.	2.2	22
70	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. Leukemia, 2021, 35, 3092-3100.	7.2	22
71	The impact of CD34^{+} cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation. Pediatric Blood and Cancer, 2009, 53, 1100-1106.	1.5	21
72	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. OncoImmunology, 2016, 5, e1250992.	4.6	21

#	Article	IF	Citations
73	Recipient–donor KIR ligand matching prevents CMV reactivation post–haploidentical T cell–replete transplantation. British Journal of Haematology, 2017, 177, 766-781.	2.5	21
74	Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. Journal of Immunology Research, 2017, 2017, 1-8.	2.2	21
75	A wave of Foxp3+ regulatory T cell accumulation in the neonatal liver plays unique roles in maintaining self-tolerance. Cellular and Molecular Immunology, 2020, 17, 507-518.	10.5	21
76	Expression of CD62L on Donor CD4+ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation. Journal of Clinical Immunology, 2009, 29, 696-704.	3.8	20
77	Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Review of Hematology, 2018, 11, 273-284.	2.2	20
78	High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Annals of Hematology, 2009, 88, 1015-1024.	1.8	19
79	The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA–mismatched/haploidentical hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2011, 57, 135-141.	1.5	19
80	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. Journal of Infection, 2016, 73, 261-270.	3.3	19
81	Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. Annals of Hematology, 2017, 96, 567-574.	1.8	19
82	Effects of pre–and post–transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen–matched or mismatched related donor allografts. American Journal of Hematology, 2017, 92, E659-E661.	4.1	19
83	The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplantation, 2019, 54, 567-577.	2.4	19
84	Characterization of CD3+CD4ˉCD8ˉ (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation. Transplant Immunology, 2011, 25, 180-186.	1.2	18
85	Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. American Journal of Hematology, 2011, 86, 227-230.	4.1	18
86	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte–colony–stimulating factor–mobilized marrow harvests and peripheral blood harvests. Transfusion, 2015, 55, 2874-2881.	1.6	18
87	Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. Blood Advances, 2019, 3, 1416-1428.	5.2	18
88	The Quantification of Minimal Residual Disease Pre–and Post–Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 75-87.	1.5	18
89	Mutation topography and risk stratification for *de novo* acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (*NPM1*) mutation or Fms–like tyrosine kinase 3 internal tandem duplication (*FLT3–*ITD). British Journal of Haematology, 2020, 190, 274-283.	2.5	18
90	Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2+T cells activities after hematopoietic transplantation for blood malignancies. , 2020, 8, e000208.		18

#	Article	IF	Citations
91	An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood, 2022, 140, 516-520.	1.4	18
92	Rapid Recovery of CD3+CD8+ T Cells on Day 90 Predicts Superior Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation. PLoS ONE, 2016, 11, e0156777.	2.5	17
93	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Frontiers in Oncology, 2020, 10, 320.	2.8	17
94	Effect of the inÂvivo application of granulocyte colonyâ€stimulating factor on <scp>NK</scp> cells in bone marrow and peripheral blood. Journal of Cellular and Molecular Medicine, 2018, 22, 3025-3034.	3.6	15
95	Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. Functional and Integrative Genomics, 2018, 18, 287-299.	3.5	15
96	The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2018, 97, 1547-1554.	1.8	15
97	Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. Leukemia and Lymphoma, 2019, 60, 2181-2189.	1.3	15
98	The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. Annals of Hematology, 2020, 99, 73-82.	1.8	15
99	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cellular and Molecular Immunology, 2022, 19, 482-491.	10.5	15
100	Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome. Leukemia and Lymphoma, 2013, 54, 2671-2677.	1.3	14
101	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology, 2018, 97, 485-495.	1.8	14
102	Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. Science China Life Sciences, 2018, 61, 902-911.	4.9	14
103	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia, 2022, 36, 267-270.	7.2	14
104	Interferon-Î± as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2949-2956.	1.3	14
105	Adoptive therapy with <scp>cytomegalovirus</scp>â€specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy. American Journal of Hematology, 2022, 97, 762-769.	4.1	14
106	Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. Science China Life Sciences, 2016, 59, 1139-1148.	4.9	13
107	Thrombotic microangiopathy with concomitant <scp>GI</scp> aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. European Journal of Haematology, 2018, 100, 171-181.	2.2	13
108	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2659-2670.	1.8	13

#	Article	IF	Citations
109	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. Journal of Hematology and Oncology, 2020, 13, 52.	17.0	13
110	Autophagy in endothelial cells regulates their haematopoiesis-supporting ability. EBioMedicine, 2020, 53, 102677.	6.1	13
111	The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in <i>CBFB–MYH11</i>–positive acute myeloid leukaemia indicates poor prognosis. British Journal of Haematology, 2021, 192, 265-271.	2.5	13
112	Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Frontiers in Immunology, 2022, 13, 757002.	4.8	13
113	Non-traditional CD4+CD25−CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation. Journal of Translational Medicine, 2014, 12, 187.	4.4	12
114	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Letters, 2019, 442, 193-201.	7.2	12
115	Characteristics and influencing factors of CD19+ B cell reconstitution in patients following haploidentical/mismatched hematopoietic stem cell transplantation. International Journal of Hematology, 2012, 96, 109-121.	1.6	11
116	IL-35 inhibits acute graft-versus-host disease in a mouse model. International Immunopharmacology, 2015, 29, 383-392.	3.8	11
117	Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. OncoImmunology, 2016, 5, e1242546.	4.6	11
118	Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. Human Immunology, 2018, 79, 672-677.	2.4	11
119	Effects of Low-Dose Glucocorticoid Prophylaxis on Chronic Graft-versus-Host Disease and Graft-versus-Host Disease–Free, Relapse-Free Survival after Haploidentical Transplantation: Long-Term Follow-Up of a Controlled, Randomized Open-Label Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 529-537.	2.0	11
120	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplantation, 2020, 55, 2035-2042.	2.4	11
121	Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE, 2013, 8, e58735.	2.5	11
122	Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective. Frontiers in Oncology, 2021, 11, 758512.	2.8	11
123	Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft?. Seminars in Hematology, 2019, 56, 201-208.	3.4	10
124	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Annals of Hematology, 2021, 100, 1203-1212.	1.8	10
125	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood, 2021, , .	1.4	10
126	Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Annals of Hematology, 2018, 97, 641-654.	1.8	9

#	Article	IF	Citations
127	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 600-608.	2.4	9
128	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1203-1209.	2.0	9
129	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2097-2107.	2.4	9
130	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	1.3	8
131	Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin $\beta 1$ signaling. Journal of Cancer, 2017, 8, 2212-2222.	2.5	8
132	Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. Science China Life Sciences, 2018, 61, 569-577.	4.9	8
133	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. British Journal of Haematology, 2019, 184, 788-796.	2.5	8
134	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1171-1178.	2.0	8
135	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 2087-2097.	2.4	8
136	Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation. JCI Insight, 2022, 7, .	5.0	8
137	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology, 2021, 11, 773394.	2.8	8
138	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chinese Medical Journal, 2018, 131, 2808-2816.	2.3	7
139	Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors. Bone Marrow Transplantation, 2019, 54, 1287-1294.	2.4	7
140	Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. Expert Review of Anticancer Therapy, 2020, 20, 453-464.	2.4	7
141	Predicted indirectly recognizable HLA epitopes are not associated with clinical outcomes after haploidentical hematopoietic stem cell transplantation. Human Immunology, 2018, 79, 117-121.	2.4	7
142	Multiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graft†Versus†Host Disease. Advanced Science, 2022, 9, e2200978.	11.2	7
143	IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. Annals of Hematology, 2018, 97, 1399-1406.	1.8	6
144	Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts. Frontiers of Medicine, 2018, 12, 153-163.	3.4	6

#	Article	IF	Citations
145	Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation. Clinical Immunology, 2019, 205, 49-56.	3.2	6
146	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1733-1742.	1.8	6
147	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1629-1636.	2.0	6
148	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Advances, 2021, 5, 5479-5489.	5.2	6
149	Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation. Medicine (United States), 2020, 99, e23569.	1.0	6
150	Negative association of donor age with CD34â cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests. Chinese Medical Journal, 2014, 127, 3597-601.	2.3	6
151	CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clinical and Experimental Immunology, 2022, 208, 332-339.	2.6	6
152	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. Chinese Medical Journal, 2018, 131, 2185-2192.	2.3	5
153	NK cell reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with matched sibling transplantation. Science China Life Sciences, 2020, 63, 781-784.	4.9	5
154	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Advances, 2020, 4, 5846-5857.	5.2	5
155	Correlation of CD19+CD24hiCD38hi B cells in coronary artery disease with severity of atherosclerosis. Chinese Medical Journal, 2020, 133, 1257-1258.	2.3	5
156	Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. American Journal of Hematology, 2021, 96, 561-570.	4.1	5
157	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. Annals of Hematology, 2021, 100, 555-562.	1.8	5
158	Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplantation, 2022, , .	2.4	5
159	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.8	5
160	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic Advances in Hematology, 2022, 13, 204062072210952.	2.5	5
161	Decoding lymphomyeloid divergence and immune hyporesponsiveness in G-CSF-primed human bone marrow by single-cell RNA-seq. Cell Discovery, 2022, 8, .	6.7	5
162	Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia. Clinical Transplantation, 2016, 30, 954-958.	1.6	4

#	Article	IF	Citations
163	Th2 polarization in target organs is involved in the alleviation of pathological damage mediated by transplanting granulocyte colony-stimulating factor-primed donor T cells. Science China Life Sciences, 2020, 64, 1087-1096.	4.9	4
164	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology, 2021, 100, 505-516.	1.8	4
165	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. Bone Marrow Transplantation, 2021, 56, 2723-2731.	2.4	4
166	Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. Blood Advances, 2021, 5, 4910-4921.	5.2	4
167	Donor activating killer cell immunoglobulinâ€‘like receptors genes correlated with Epsteinâ€"Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2022, 196, 1007-1017.	2.5	4
168	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Frontiers in Immunology, 2021, 12, 731435.	4.8	4
169	PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome. Frontiers in Immunology, 2022, 13, 879501.	4.8	4
170	Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation. Leukemia Research, 2009, 33, 123-128.	0.8	3
171	The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts. Transplant Immunology, 2018, 48, 55-59.	1.2	3
172	CD8+CD161hi T cells are associated with acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1652-1654.	2.4	3
173	Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates. Scientific Reports, 2020, 10, 2367.	3.3	3
174	A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chinese Medical Journal, 2021, 134, 1199-1208.	2.3	3
175	Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. Current Medical Science, 2021, 41, 443-453.	1.8	3
176	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. Frontiers in Oncology, 2021, 11, 706935.	2.8	3
177	PMLâ€‘RARA transcript levels at the end of induction therapy are associated with prognosis in nonâ€‘highâ€‘risk acute promyelocytic leukaemia with allâ€‘trans retinoic acid plus arsenic in frontâ€‘line therapy: longâ€‘term followâ€‘up of a singleâ€‘centre cohort study. British Journal of Haematology, 2021, 195, 722-730.	2.5	3
178	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. Annals of Hematology, 2020, 99, 1643-1653.	1.8	3
179	Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET) Tj ETQq1 1 0.784314 rgBT /Over		
180	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	4.8	3

#	Article	IF	Citations
181	Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. Frontiers in Immunology, 0, 13, .	4.8	3
182	Peripheral blood stem cell transplantation or bone marrow transplant in allogeneic settings: Which should be chosen?. Leukemia Research, 2012, 36, e116-e117.	0.8	2
183	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. Journal of Thoracic Disease, 2016, 8, 2219-2225.	1.4	2
184	Factors affecting the CD34+ cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor. Transfusion and Apheresis Science, 2016, 55, 311-317.	1.0	2
185	Effects of Granulocyte Colony-Stimulating Factor on Proliferation and Apoptosis of B Cells in Bone Marrow of Healthy Donors. Transplantation Proceedings, 2020, 52, 345-352.	0.6	2
186	A retrospective analysis on anti-CD20 antibodyâ€"treated Epsteinâ€"Barr virusâ€"related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2649-2657.	1.8	2
187	Osteoclast stimulatory transmembrane protein (OCâ€STAMP) is a promising molecular prognostic indicator for multiple myeloma. European Journal of Haematology, 2020, 105, 185-195.	2.2	2
188	Editorial: Recent Developments in Haploidentical Hematopoietic Cell Transplantation: Therapy and Complications. Frontiers in Immunology, 2021, 12, 746221.	4.8	2
189	A Scoring System for Predicting the Prognosis of Late-Onset Severe Pneumonia after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 870.e1-870.e7.	1.2	2
190	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2022, 22, 11.	2.6	2
191	Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment. Frontiers in Oncology, 0, 12, .	2.8	2
192	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1866-1872.	2.0	1
193	HCMV modulates câ€Mpl/IEXâ€1 pathwayâ€mediated megakaryo/thrombopoiesis via PDGFRÎ± and Î±vÎ²3 receptors after alloâ€HSCT. Journal of Cellular Physiology, 2021, 236, 6726-6741.	4.1	1
194	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. Transplantation and Cellular Therapy, 2021, 27, 253.e1-253.e9.	1.2	1
195	Dead/H-Box Helicase 11 (DDX11) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice. Blood, 2019, 134, 2732-2732.	1.4	1
196	Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia. Blood, 2019, 134, 3823-3823.	1.4	1
197	PRDM1 Is Sufficient for Inducing Human Primary T Cell Hyporesponsiveness and Implicates Low Gvhd Occurrence after Allo-HSCT. Blood, 2021, 138, 197-197.	1.4	1
198	Machine-Learning Based Early Warning System for Prediction for Disseminated Intravascular Coagulation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Multicenter Study. Blood, 2021, 138, 2113-2113.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Haploidentical Transplantation Using Unmanipulated G-CSF-Primed Blood and Marrow as Allografts: Clinical Data and Challenges. , 2018, , 55-79.		0
200	Donor selection for haploidentical hematopoietic cell transplantationâ€•practice guidance. Advances in Cell and Gene Therapy, 2019, 2, e42.	0.9	0
201	Reply to M. Shibusawa et al. Journal of Clinical Oncology, 2020, 38, 4224-4225.	1.6	0
202	Comparison of Transplant Donor- and Third-Party Donor-Derived CMV-Specific T Cells for CMV Infection After Allogenic Stem Cell Transplantation. SSRN Electronic Journal, 0, , .	0.4	0
203	Superiority of Leukemic Stem Cell-Based Minimal Residual Disease Assay to Traditional Multiparameter Flow Cytometry-Based Method for Relapse Prediction in AML Patients: A Prospective Study with Randomized Training and Validation Sets. SSRN Electronic Journal, 0, , .	0.4	0
204	Comparable Immune Reconstitution Achieved Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation and HLA-Identical Sibling Transplantation. Blood, 2010, 116, 2312-2312.	1.4	0
205	Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. Blood, 2011, 118, 4161-4161.	1.4	0
206	Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial. Blood, 2014, 124, 40-40.	1.4	0
207	The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5800-5800.	1.4	0
208	Characteristics of Early Recovery of Double Negative T-Cell Subpopulations after Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 4589-4589.	1.4	0
209	Desialylation of Megakaryocytes Diminishes Platelet Production By Disrupting Megakaryocyte Adhesion, Migration and Proplatelet Formation in Chronic Immune Thrombocytopenia. Blood, 2016, 128, 165-165.	1.4	0
210	Lower Incidence of Acute Gvhd Is Associated with the Rapid Recovery of CD4+CD25+CD45RA+ Regulatory T Cells in Patients Who Received Haploidentical Allografts from NIMA-Mismatched Donors: A Retrospective (development) and Prospective (validation) Cohort-Based Study. Blood, 2016, 128, 4573-4573.	1.4	0
211	Polymorphisms of CTLA-4 Are Associated with Treatment Outcome in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens. Blood, 2016, 128, 3323-3323.	1.4	0
212	Crucial Role of Complement Activation and IL-1Î² in Bone Marrow Niche of Immune Thrombocytopenia. Blood, 2016, 128, 166-166.	1.4	0
213	Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course. Blood, 2018, 132, 5734-5734.	1.4	0
214	Poor NKG2C+ Adaptive NK Cell Recovery at Early Stage after Allo-HSCT Increased the Occurrence of Refractory Cytomegalovirus Infection. Blood, 2018, 132, 360-360.	1.4	0
215	Rituximab for Desensitization during HLA-Mismatched Stem Cell Transplantation in Patients with a Positive Donor Specific Anti-HLA Antibody: A Prospective Study. Blood, 2019, 134, 5622-5622.	1.4	0
216	Costimulatory Molecule DNAM-1 Is Essential for Optimal NK Education Post Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 3291-3291.	1.4	0

#	Article	IF	Citations
217	Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3-itd Mutation. Blood, 2019, 134, 1421-1421.	1.4	0
218	Contribution of Myeloid-Drived Suppressor Cells to Leukemia Relapse in Patients with B-ALL Who Underwent Allo-HSCT. Blood, 2019, 134, 2010-2010.	1.4	0
219	Risk Factors and Different Therapeutic Patterns of Late-Onset Hemorrhagic Cystitis after Haploidentical Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 3261-3261.	1.4	0
220	Autophagy in Endothelial Cells Regulates Their Hematopoiesis Supporting Ability. Blood, 2019, 134, 4425-4425.	1.4	0
221	Observation on the Efficacy of Consolidation Chemotherapy Combined with Allogeneic Natural Killer Cell Infusion in the Treatment of Low and Moderate Risk AML. Blood, 2019, 134, 1378-1378.	1.4	0
222	Donor and Host Coexpressing KIR Ligands Promote NK Education Post Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 4519-4519.	1.4	0
223	Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia. Hematology, 2021, 26, 9-15.	1.5	0
224	Treatment Outcome and Efficacy of Therapeutic Plasma Exchange for Transplant-Associated Thrombotic Microangiopathy in a Real-World Large Cohort Study. Blood, 2021, 138, 1013-1013.	1.4	0
225	A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion. Blood, 2021, 138, 4468-4468.	1.4	0
226	Prevalence and Risk Factors of Antibodies to Class I and II Human Leukocyte Antigens in Haploidentical Allograft Candidates: A Prospective Study on 3805 Subjects. Blood, 2021, 138, 2880-2880.	1.4	0
227	All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP. Blood, 2021, 138, 15-15.	1.4	0
228	The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study. Blood, 2021, 138, 2320-2320.	1.4	0
229	Comparison of Transplant Donor and Third-Party Donor Derived CMV-Specific T Cells for CMV Infection after Allogenic Stem Cell Transplantation. Blood, 2021, 138, 1701-1701.	1.4	0
230	Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes. Blood, 2020, 136, 42-43.	1.4	0
231	Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 16-17.	1.4	0
232	Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia. Blood, 2020, 136, 4-5.	1.4	0
233	Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions. Oncology and Therapy, 2022, , 1.	2.6	0
234	Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.. Journal of Clinical Oncology, 2022, 40, 7052-7052.	1.6	0

#	Article	IF	Citations
235	Prognostic value of post‐transplantation Wilms' tumor gene 1 expression in acute myeloid leukaemia subgroup according to different pre‐transplant disease status. International Journal of Laboratory Hematology, 2022, 44, .	1.3	0